FDMT Insider Shawn Tomasello Buys 50,000 Shares

Shawn Tomasello Joins Insider Buying Wave at 4D Molecular Therapeutics

Shawn Tomasello purchased 50,000 shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT) on June 17, 2026. This transaction was part of a larger, coordinated round of open-market purchases executed by several company insiders on the exact same day.

Inside the June 17 Insider Purchases

The mid-June buying spree involved a broad group of company insiders acquiring stock simultaneously. On June 17, 2026, Nancy Miller-Rich picked up 50,000 shares, Jacob Chacko acquired 50,000 shares, and John Milligan bought 75,000 shares. Additional purchases on that date included 50,000 shares by Susannah Gray, 50,000 shares by Glenn Sblendorio, and 50,000 shares by Charles Theuer. These parallel transactions highlight a shared alignment among leadership regarding the biotechnology firm's pipeline progress.

Stock Performance and Recent Trading Levels

Shares of 4D Molecular Therapeutics recently traded around $9.66 on the NasdaqGS. The biotechnology company carries a market capitalization of approximately $841.9 million. Because the firm focuses on developing gene therapies and remains in a clinical research phase, it currently has no meaningful P/E ratio due to negative earnings. The stock trades well below its 50-day moving average of $12.80 while hovering near its 200-day moving average of $10.28, giving investors a look at how the shares have shifted over recent months.

Recent Earnings and Financial Standing

For its recent financial period, the company reported $92.0 million in revenue alongside a revenue growth rate of 251.1%. However, the firm posted an earnings per share loss of $2.63. Profitability metrics reflect the heavy capital requirements of biotech research, showing a net margin of -1.95% and a return on equity of -0.43%. Market participants will look toward the next earnings release scheduled for November 10, 2026, for fresh updates on clinical trials.

Wall Street Analyst Ratings and Price Targets

Analysts covering the stock remain active with regular updates to their coverage. On October 6, 2026, Chardan Capital maintained a buy rating while adjusting its target to $25.00. Earlier, B of A Securities maintained a buy rating on September 29, 2026, lifting its target to $33.00, while Cantor Fitzgerald upgraded the stock to overweight with a $20.00 target on September 14, 2026. B. Riley Securities initiated coverage with a buy rating and a $37.00 target on July 31, 2026, and HC Wainwright & Co. reiterated a buy rating with a $36.00 target on July 20, 2026. Overall, the consensus recommendation stands at a strong buy, with a mean price target of $27.82 across 11 analyst opinions.

About 4D Molecular Therapeutics

Headquartered in Emeryville, California, 4D Molecular Therapeutics is a late-stage biotechnology firm focused on creating genetic medicines using proprietary adeno-associated virus vectors. Its therapeutic platform generates candidates designed to treat retinal vascular diseases, cystic fibrosis, and other severe conditions through targeted delivery. These clinical efforts rely heavily on ongoing research collaborations and licensing agreements.

Looking Ahead for Shareholders

Investors tracking the firm will likely monitor upcoming clinical data milestones and the financial updates expected during the November 10 earnings release. Insider transactions and institutional filings offer a window into how stakeholders view the company's long-term vector platform, though these historical reports do not guarantee future stock movements.